Stock Events

Stock Events

Evotec

€2.18

0

-€0-0% Friday 19:46

Statistics

Day High

2.18

Day Low

2.1

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6MayExpected

Next

-0.18

0.16

0.49

0.82

Expected EPS

-0.17735391648

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVTA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

CRISPR Therapeutics

CRISPR Therapeutics is involved in gene editing, a field that overlaps with Evotec's drug discovery platforms, making them direct competitors in the biotech innovation space.

Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on creating new treatments for serious diseases, directly competing with Evotec's drug discovery and development services.

Novartis is a large pharmaceutical company that competes with Evotec in the drug discovery and development sector, particularly in the development of novel therapeutics.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that competes with Evotec in the area of drug discovery, development, and commercialization, especially in the fields of antiviral drugs.

Amgen is a biotechnology firm focusing on human therapeutics, competing with Evotec in drug discovery and development, particularly in the biotech sector.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, competing with Evotec in drug discovery and development, especially in the area of monoclonal antibodies.

Biomarin Pharmaceutical

BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases, competing with Evotec in the niche market of rare diseases drug discovery.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with Evotec in the development of novel RNA-based therapies.

Beam Therapeutics

Beam Therapeutics competes with Evotec in the cutting-edge field of gene editing, specifically using base editing technology to develop precision genetic medicines.

About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Show more...

CEO

Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.

Employees

4715

Country

Germany

ISIN

US30050E1055

Listings

0 Comments

Share your thoughts

FAQ

What is Evotec stock price today?▼

The current price of EVTA.STU is €2.18 EUR — it has decreased by -0% in the past 24 hours. Watch Evotec stock price performance more closely on the chart.

What is Evotec stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Evotec stocks are traded under the ticker EVTA.STU.

When is the next Evotec earnings date?▼

Evotec is going to release the next earnings report on May 06, 2026.

How many employees does Evotec have?▼

As of April 11, 2026, the company has 4,715 employees.

In which sector is Evotec located?▼

Evotec operates in the Health & Wellness sector.

When did Evotec complete a stock split?▼

Evotec has not had any recent stock splits.

Where is Evotec headquartered?▼

Evotec is headquartered in Hamburg, Germany.